
AI-generated summary
Juul Labs previously dominated the U.S. e-cigarette market but faced intense regulatory scrutiny, lawsuits, and declining sales due to concerns over teen vaping. The company discontinued fruit and candy flavors in 2019 and has paid approximately $3 billion in settlements.
WASHINGTON -- Vaping company Juul Labs on Friday received federal permission to sell an updated version of its e-cigarette, which includes an optional age-verification system designed to prevent underage use.
The decision from the Food and Drug Administration allows the company to sell a new version of its top-selling vaping device for the first time since it launched more than a decade ago. In recent years the company has had to lay off hundreds of employees while paying roughly $3 billion to settle government and private lawsuits over teen use of its products.
Juul plans to market the new device under the brand name Juul2, along with updated versions of its tobacco- and menthol-flavored cartridges. In 2019, the company discontinued several fruit and candy flavors that drove most of its sales but were favored by teens.
The latest announcement is not an approval or endorsement, and people who do not smoke should not use Juul or any other e-cigarettes, according to regulators. The FDA determination indicates that smokers who switch completely to Juul can reduce their exposure to deadly carcinogens and other chemicals found in traditional cigarettes.
According to company studies reviewed by the FDA, between 20% to 50% of smokers who used Juul products were able to stop smoking at the end of six weeks. The rates of quitting varied based on the flavors and nicotine strengths used.
The new device also gives users the option to require age verification via an online app before the e-cigarette can be unlocked.
The FDA has authorized a handful of e-cigarettes to help adult smokers quit or cut back on cigarettes. In May, the FDA OK'd the first fruit-flavored electronic cigarettes intended for adult smokers. The approval represented a major policy shift and came after months of appeals to President Donald Trump from the vaping industry.
Juul is no longer the top-selling e-cigarette brand in the U.S. and trails Vuse, which is sold by tobacco giant Reynolds American. Reynolds also makes Camel and Newport cigarettes.
Teens have shifted away from Juul as part of a wider drop in vaping, according to federal figures. Teens who continue to vape mostly use unauthorized disposable e-cigarettes imported from China, which come in fruit and candy flavors.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
AI outlook — possibilities, not facts
Juul2 will capture a modest share of the regulated e-cigarette market within six months of launch
Possible · Within months

Psychologist Diana Hill explains body image flexibility as a way to cope with negative thoughts about appearance without requiring self-love, offering practical exercises to redirect focus from looks to internal awareness, bodily functionality, and values-driven actions amid societal pressures from weight loss drugs and social media.

The FDA has approved Gilead's Bixlenvo, a once-daily HIV pill combining bictegravir and lenacapavir. Designed for patients with suppressed virus who require complex regimens or seek alternatives, it aims to simplify treatment and preserve future options.

Health Secretary Robert F. Kennedy Jr. has posted anti-vaccine misinformation on social media following the first measles-linked deaths in Pennsylvania in 35 years, which included a newborn baby.

Medicare's Bridge program, which provides obesity drugs for $50 monthly, has seen significant uptake with CVS and Walgreens filling 200,000 prescriptions in under two months. The pilot aims to improve health outcomes for eligible seniors through 2027.

The FDA has granted expedited approval to Rasonque (daraxonrasib), a daily pill by Revolution Medicines for advanced pancreatic cancer. Clinical studies showed the drug nearly doubled median survival time for patients with metastatic cancer by targeting KRAS mutations.

Following the expiration of federal Affordable Care Act subsidies, approximately 440,000 Floridians have dropped their health insurance. Residents are struggling with rising premiums and medical costs, forcing many to rely on charitable clinics or delay necessary care.